HomeCompareZURVY vs JNJ

ZURVY vs JNJ: Dividend Comparison 2026

ZURVY yields 4.79% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZURVY wins by $1.86M in total portfolio value
10 years
ZURVY
ZURVY
● Live price
4.79%
Share price
$35.51
Annual div
$1.70
5Y div CAGR
57.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.89M
Annual income
$1,313,045.37
Full ZURVY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ZURVY vs JNJ

📍 ZURVY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZURVYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZURVY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZURVY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZURVY
Annual income on $10K today (after 15% tax)
$406.84/yr
After 10yr DRIP, annual income (after tax)
$1,116,088.56/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ZURVY beats the other by $1,112,102.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZURVY + JNJ for your $10,000?

ZURVY: 50%JNJ: 50%
100% JNJ50/50100% ZURVY
Portfolio after 10yr
$960.8K
Annual income
$658,867.39/yr
Blended yield
68.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ZURVY
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
Altman Z
0.7
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZURVY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZURVYJNJ
Forward yield4.79%2.13%
Annual dividend / share$1.70$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR57.4%28%
Portfolio after 10y$1.89M$30.3K
Annual income after 10y$1,313,045.37$4,689.40
Total dividends collected$1.81M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ZURVY vs JNJ ($10,000, DRIP)

YearZURVY PortfolioZURVY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,453$753.37$10,592$272.30+$861.00ZURVY
2$13,524$1,269.30$11,289$357.73+$2.2KZURVY
3$16,676$2,204.80$12,123$472.89+$4.6KZURVY
4$21,842$3,999.09$13,141$629.86+$8.7KZURVY
5$31,077$7,705.32$14,408$846.81+$16.7KZURVY
6$49,379$16,126.74$16,021$1,151.60+$33.4KZURVY
7$90,529$37,694.12$18,122$1,588.22+$72.4KZURVY
8$198,525$101,658.65$20,930$2,228.20+$177.6KZURVY
9$540,359$327,937.66$24,792$3,191.91+$515.6KZURVY
10$1,891,230$1,313,045.37$30,274$4,689.40+$1.86MZURVY

ZURVY vs JNJ: Complete Analysis 2026

ZURVYStock

Zurich Insurance Group AG, together with its subsidiaries, provides insurance products and related services in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company operates through Property & Casualty Regions, Life Regions, Farmers, Group Functions and Operations, and Non-Core Businesses segments. It offers car, home, travel, general liability, life and critical illness, worker injury, and other insurance products; and saving and investment, and pension and retirement planning products. The company also provides property, casualty, management or professional liability, trade credit, political risk, marine, cyber risk, and financial institution insurance products. In addition, it offers employee benefit insurance products; reinsurance services; and non-claims and ancillary services to the farmers' exchanges. It serves individuals, small businesses, and mid-sized and large companies, as well as multinational corporations. The company sells its products through agents, brokers, and bank distribution channels. Zurich Insurance Group AG was founded in 1872 and is based in Zurich, Switzerland.

Full ZURVY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ZURVY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZURVY vs SCHDZURVY vs JEPIZURVY vs OZURVY vs KOZURVY vs MAINZURVY vs ABBVZURVY vs MRKZURVY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.